# Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

> **NCT03119636** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **BIOLOGICAL:** NPC transplantation
- **DRUG:** Levodopa

## Key facts

- **NCT ID:** NCT03119636
- **Lead sponsor:** Chinese Academy of Sciences
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05
- **Primary completion:** 2018-11
- **Final completion:** 2020-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119636, "Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03119636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*